Skip to content

Hyris Technology Supports the Fight Against One of the World’s Deadliest Diseases, Malaria

Hyris 3 mins read

Hyris' molecular diagnostic technology has been adapted to enable real-time surveillance of mosquito vector insecticide resistance, which will aid in malaria control campaigns.

LONDON, UK / ACCESSWIRE / February 20, 2024 / Hyris, working with an international team of researchers, has developed a prototype field-deployable surveillance system to detect insecticide-resistant malaria vector mosquitoes in the field without the need for transportation to sophisticated laboratories. The prototype can diagnose a mosquito for insecticide resistance at the field site three or less hours after capture. Current approaches can take up to six months since samples must be collected in remote areas and then transported to centralized laboratories for testing.

Hyris fights malaria
Hyris fights malaria
Disease vector mosquito

The early and cost-effective detection of mosquito resistance to insecticides is essential for planning and implementing effective malaria control strategies. Mosquito-killing insecticides remain key weapons in preventing malaria transmission in sub-Saharan Africa and other malaria-endemic parts of the world. However, mosquitoes often develop resistance to insecticides, rendering them ineffective in disrupting the spread of the disease.

The research team is led by Professor George Dimopoulos at the Johns Hopkins Bloomberg School of Public Health and the Johns Hopkins Malaria Research Institute, and together with Professor Charles Wondji at the Centre for Research in Infectious Diseases in Yaoundé, Cameroon the team has been working since 2021 conducting laboratory R&D, and field testing in malaria-endemic areas of Cameroon. This is enabled by the distinctive features of the Hyris System™ for molecular testing that is based on a simple portable battery-powered device rather than a heavy laboratory-based benchtop machine.

The newly developed Hyris technology of pre-filled dried cartridges enables running the diagnostic assay by simply adding the mosquito sample to a well already containing all other reagents, simplifying the testing workflow. The stability of the dried reagents enables their storage at room temperature for up to six months thereby not requiring freezers which are lacking at most sample collection sites in the field.

This research project was supported by a Bill & Melinda Gates Foundation grant made to Johns Hopkins University.

"This new test is deployable right in-field," explains Lorenzo Colombo, CTO and Managing Director at Hyris. "Our technology enables researchers to collect a mosquito sample in the field and conduct the molecular diagnostic assay right there, with real-time acquisition, from a central lab, of insecticide resistance data from the disease-endemic area."

The team is currently exploring the path for nationwide deployment of the mosquito insecticide resistance surveillance system in Cameroon, something that would enable real-time informed decision-making on malaria mosquito control campaigns using the most effective insecticides.

Stefano Lo Priore, Founder and CEO at Hyris, further explains the advantages of this new test: "The necessity of cold chain has always been a critical roadblock for any test distribution in remote areas. This new malaria mosquito insecticide resistance test does not require any cold chain for shipping, making it one hundred percent field-deployable." Lo Priore also highlights how such projects perfectly align with Hyris' commitment to developing advanced biotech solutions for critical environments. "We work to provide increasingly efficient ways to manage outbreak readiness and health prevention, especially in the most challenging situations."

For more information, feel free to contact a Hyris specialist at

Contact Information

Gabriele Salaris
Global Experience Manager
+39 345 555 3379

SOURCE: Hyris Ltd


View the original press release on

More from this category

  • Biotechnology, Medical Health Aged Care
  • 16/07/2024
  • 13:13
Monash University

New study finds Victoria’s approach to post-heart attack medicine strategies are inconsistent

A new study led by Monash University has revealed that medicine strategies following a heart attack vary from patient to patient, despite clear clinical…

  • Contains:
  • Biotechnology
  • 15/07/2024
  • 20:11
Moolec Science SA

Moolec Signs an Offtake Agreement With Major Global CPG Company to Hit the US Market in 2025

LUXEMBOURG / ACCESSWIRE / July 15, 2024 / Moolec Science SA (NASDAQ:MLEC) ("the Company"), a Molecular Farming ingredient company, announced today the signing of an offtake agreement with one of the largest global consumer packaged goods and pet food companies for the use of Moolec's patented science-based GLA Safflower Oil product, GLASO™ (the "Agreement"). This initial offtake agreement has a term of three years and establishes commercial conditions for the delivery of GLASO™ in US territory with an initial estimated volume of 50 tons for 2025.Moolec Science Logo GLASO™ is a nutritional omega 6 oil obtained from bioengineered safflower seeds.…

  • Biotechnology, Government VIC
  • 11/07/2024
  • 14:35
La Trobe University

MEDIA OPP: Launch of Bio Innovation Hub opens scope for new disease treatments

What: Victorian Government Minister Colin Brooks, representing the Minister for Training and Skills Gayle Tierney, and LaTrobe University Vice-Chancellor ProfessorTheo Farrell, will Launch the new $8 million state-of-the-art Bio Innovation Hub at La Trobe'sMelbourne campus in Bundoora. The purpose-built facility will support the development of world-leading biotechnology and agri-technology businesses. It includes PC2 “wet” laboratories – joining just a handful of the sought-after labs in the state – and world-class equipment to help businesses commercialise their research discoveries. VivaZome CEO and Managing Director Xenia Sango will outline the development of a new treatment that could potentially reverse or stop progression…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.